IP Library Granted Patent US 8,497,242
Granted Patent B2
US 8,497,242 · App. 13/036,484 · Granted Jul 30, 2013

Processes for intermediates for macrocyclic compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,497,242
App. No.
13/036,484
Granted
Jul 30, 2013
Kind
B2
Abstract

The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

Claims (23)

1. A compound having the following structure:

wherein:

W is selected from the group consisting of —NHPG and —NH 2 ,

X is —OH or —OPG; and

PG is a protecting group.

2. The compound of claim 1 , wherein W is —NHPG.

3. The compound of claim 1 , wherein the protecting group on the nitrogen is selected from the group consisting of benzothiazole-2-sulfonyl (Bts), t-butyloxycarbonyl (Boc), carbobenzyloxy (Cbz), α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl (Ddz), 9-fluorenylmethyloxycarbonyl (Fmoc) and allyloxycarbonyl (Alloc).

4. The compound of claim 1 , wherein the protecting group on the oxygen is selected from the group consisting of tetrahydropyranyl (THP), tert-butyldimethylsilyl (TBDMS), acetyl (Ac) and benzoyl (Bz).

5. The compound of claim 1 having the following structure:

6. The compound of claim 1 having the following structure:

7. The compound of claim 1 having the following structure:

8. The compound of claim 1 having the following structure:

9. The compound of claim 8 , wherein the protecting group is α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl (Ddz) or t-butyloxycarbonyl (Boc).

10. The compound of claim 9 having the following structure:

11. The compound of claim 9 having the following structure:

12. The compound of claim 9 having the following structure:

13. The compound of claim 9 having the following structure:

14. A compound having the following structure:

wherein:

W is —OPG,

X is —OH or —OPG; and

PG is a protecting group.

15. The compound of claim 14 , wherein the protecting group on the oxygen is selected from the group consisting of tetrahydropyranyl (THP), tert-butyldimethylsilyl (TBDMS), acetyl (Ac) and benzoyl (Bz).

Assignments (4)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 044949, FRAME 0634 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0460 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Dec 22, 2017
From: OCERA THERAPEUTICS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 044949/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2015
From: TRANZYME PHARMA INC.
To: TRANZYME HOLDINGS ULC
Reel/Frame 037297/0405 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2015
From: TRANZYME HOLDINGS ULC
To: OCERA THERAPEUTICS INC.
Reel/Frame 037297/0504 →